ACADIA PHARMACEUTICALS ($ACAD) posted quarterly earnings results for Q1 2026 on Wednesday, May 6th. The company reported earnings of $0.02 per share, missing estimates of $0.06 by $0.04. The company also reported revenue of $268,060,000, missing estimates of $286,324,465 by $-18,264,465.
Stock price change since market close: -4.47%
You can see Quiver Quantitative's $ACAD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ACADIA PHARMACEUTICALS Insider Trading Activity
ACADIA PHARMACEUTICALS insiders have traded $ACAD stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $ACAD stock by insiders over the last 6 months:
- JAMES M DALY sold 30,000 shares for an estimated $670,983
- MARK C. SCHNEYER (EVP, CHIEF FINANCIAL OFFICER) has made 0 purchases and 6 sales selling 23,862 shares for an estimated $538,785.
- ADAMS CATHERINE OWEN (Chief Executive Officer) sold 11,641 shares for an estimated $249,932
- JENNIFER J RHODES (EVP, CHIEF LEGAL OFFICER, SEC) has made 0 purchases and 2 sales selling 10,794 shares for an estimated $245,021.
- JAMES KIHARA (PRINCIPAL ACCOUNTING OFFICER) has made 0 purchases and 6 sales selling 8,388 shares for an estimated $190,539.
- ELIZABETH H.Z. THOMPSON (EVP, Head of Research & Dev) sold 3,435 shares for an estimated $73,749
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
ACADIA PHARMACEUTICALS Hedge Fund Activity
We have seen 152 institutional investors add shares of ACADIA PHARMACEUTICALS stock to their portfolio, and 165 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 1,890,954 shares (+127.2%) to their portfolio in Q4 2025, for an estimated $50,507,381
- MARSHALL WACE, LLP removed 1,865,502 shares (-79.1%) from their portfolio in Q4 2025, for an estimated $49,827,558
- RTW INVESTMENTS, LP removed 1,851,023 shares (-20.6%) from their portfolio in Q4 2025, for an estimated $49,440,824
- CITIGROUP INC removed 1,490,386 shares (-94.7%) from their portfolio in Q4 2025, for an estimated $39,808,210
- TANG CAPITAL MANAGEMENT LLC removed 1,200,000 shares (-80.0%) from their portfolio in Q4 2025, for an estimated $32,052,000
- CITADEL ADVISORS LLC added 1,043,939 shares (+322.7%) to their portfolio in Q4 2025, for an estimated $27,883,610
- MILLENNIUM MANAGEMENT LLC removed 929,561 shares (-62.7%) from their portfolio in Q4 2025, for an estimated $24,828,574
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
ACADIA PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ACAD in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 02/23/2026
- UBS issued a "Buy" rating on 01/06/2026
- Citigroup issued a "Buy" rating on 01/06/2026
- JP Morgan issued a "Overweight" rating on 11/17/2025
To track analyst ratings and price targets for ACADIA PHARMACEUTICALS, check out Quiver Quantitative's $ACAD forecast page.
ACADIA PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ACAD recently. We have seen 12 analysts offer price targets for $ACAD in the last 6 months, with a median target of $34.5.
Here are some recent targets:
- Tazeen Ahmad from B of A Securities set a target price of $29.0 on 03/25/2026
- Tessa Romero from JP Morgan set a target price of $34.0 on 03/04/2026
- Paul Matteis from Stifel set a target price of $24.0 on 02/26/2026
- Brian Abrahams from RBC Capital set a target price of $30.0 on 02/26/2026
- Jason N. Butler from Citizens set a target price of $35.0 on 02/26/2026
- Ritu Baral from TD Cowen set a target price of $37.0 on 02/26/2026
- Rudy Li from Wolfe Research set a target price of $33.0 on 02/24/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
